Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
21000 participants
OBSERVATIONAL
2023-07-20
2024-01-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A sample of 800 000 people will be used to learn about the entire French population. Participants will be asked to respond to an anonymous digital survey.
The ultimate goal of this work is to have quality information to help facilitate therapeutic efforts in support of those who may need it.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of Virtual Reality Therapy in Alcohol Use Disorder Study
NCT06104176
Effect of the Enriched Environment on the Risk of Relapse
NCT05577741
Digital Detox Study
NCT06910371
Addictology Expert Patients' Fields of Intervention
NCT04458987
Virtual Reality Exposure Therapy in the Treatment of Alcohol Use Disorder
NCT05841823
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
From the perspective of social media addiction, research has shown that there is a fine line between habitual, frequent, unproblematic use and problematic and possibly addictive use of social media. Users who express symptoms and consequences traditionally associated with substance addiction (salience, mood changes, tolerance phenomenon, craving, withdrawal, relapse) could be addicted to social media.
Nowadays, abstinence from digital media and consumption cannot realistically be achieved in the context of SR addiction, as the internet and social media have become essential parts of our lives. Rather than shutting down social media altogether, therapy should focus on establishing controlled social media use and digital media awareness.
This study will be carried out to evaluate the methods of consumption (work/outside work), the characteristics of the tools used, the addictive risk, the consequences on mental and physical health and the impact on quality of life of people exposed to screens and smartphones.
A sample of 800 000 people will be used to learn about the entire French population. Participants will be asked to respond to an anonymous digital survey.
This is an observational study questionnaire-based. The ultimate goal of this work is not to overpathologize daily behaviours, but to have quality information to help facilitate therapeutic efforts in support of those who may need it.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
survey
questionnaires
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* members of the PRO-BTP insurance (email list)
* understanding French language
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Rafael
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut Rafael
Levallois-Perret, Île-de-France Region, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-A00312-43
Identifier Type: OTHER
Identifier Source: secondary_id
IR-2023/0001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.